Advertisement

Expression of Cysteine Protease Inhibitors Stefin A, Stefin B, and Cystatin C in Human Lung Tumor Tissue

  • Eileen Ebert
  • Bernd Werle
  • Britta Jülke
  • Natasa Kopitar-Jerala
  • Janko Kos
  • Tamara Lah
  • Magnus Abrahamson
  • Eberhard Spiess
  • Werner Ebert
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 421)

Abstract

In human lung tumor tissue specimen (n=73) concentrations of stefins A and B were found to be increased 2.0-fold (p<0.01) and 1.3-fold (p<0.01), respectively, as compared to matched normal tissue. Stefn A and B concentrations were higher in primary tumors than in secondary tumors, i.e. metastases from other organs to the lung (p<0.01; p<0.05, respectively). Cystatin C concentrations were rather low and did not differ between tumor and normal tissue. Both concentrations of stefins did not correlate with TNM stages. Stefin A was higher in squamous cell carcinoma than in adenocarcinoma (p<0.01), while stefin B did not show such a difference. At investigation of a relationship between survival probability of patients with primary tumors it was found that increased stefin B concentrations and total cysteine-protease-inhibitory activities but not stefin A concentrations were positively correlated with survival probability.

It is concluded that stefins A and B are major contributors to the cysteine protease inhibitory activity in primary lung tumors. Stefin B proved to be a prognostic factor, especially in squamous cell carcinoma.

Keywords

Squamous Cell Carcinoma Cysteine Protease Lung Tumor Normal Lung Tissue Large Cell Carcinoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Sloane, B. F., K. Moin, E. Krepela, and J. Rozhin. 1990. Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. Cancer Met. Rev. 9, 333–352.CrossRefGoogle Scholar
  2. 2.
    Kane E., and M. M., Gottesman. 1990. The role of cathepsin L in malignant transformation. Semin. Cancer Biol. 1, 127–136.PubMedGoogle Scholar
  3. 3.
    Sloane B. F., K. Moin, and T. T. Lah. 1994. Regulation of lysosomal endopeptidases in malignant neoplasia. In G. Thomas, II. Pretlow, and Th. P. Pretlow, editors, Biochemical and molecular aspects of selected cancers, Academic Press, Toronto, Vol. 2, 411–466.Google Scholar
  4. 4.
    Turk V., and W. Bode. 1991. The cystatins: protein inhibitors of cysteine proteinases. FEBS Lett. 285, 213–219.PubMedCrossRefGoogle Scholar
  5. 5.
    Lah T.T., J. L. Clifford, K. Helmer, N. Day, K. Moin, K. V. Honn, J. D. Crissman, and B. F. Sloane. 1989. Inhibitory properties of low molecular weight cysteine proteinase inhibitors from human sarcoma. Biochim. Biophys. Acta 993, 63–73.PubMedCrossRefGoogle Scholar
  6. 6.
    Calkins C. C., and B. F. Sloane. 1995. Mammalian cysteine protease inhibitors: biochemical properties and possible roles in tumor progression. Biol. Chem. Hoppe-Seyler 376, 71–80.PubMedGoogle Scholar
  7. 7.
    Knoch H., B. Werle, W. Ebert, and E. Spiess. 1994. Imbalance between cathepsin B and cysteine proteinase inhibitors is of prognostic significance in human lung cancer. Int..1. Oncol. 5, 77–85.Google Scholar
  8. 8.
    Kyllönen, A. P., M. Järvinen, V. K. Hopsu-Havu, A. Dom, O. Räsänen, T. Larmi, and A. Rinne. 1984. The behaviour of small molecular cysteme proteinase inhibitors in lung cancers and in surrounding tissue. Acta. Histochem. 74, 109–113.PubMedCrossRefGoogle Scholar
  9. 9.
    Pyykkönen K., T. Räsänen, M. Järvinen, R. Rinne, and O. Räsänen. 1996. lmmunolocalization of cystatin A in different types of the lung carcinomas. In INTERNATIONAL COMMITTEE ON PROTEOLYSIS, editors, 1 Ith International Conference on Proteolysis and Protein Turnover, p. 135, Turku.Google Scholar
  10. 10.
    World Health Organization: Histological classification of lung tumors, WHO, Geneva (1981).Google Scholar
  11. 11.
    Hermanek P., and L. Sobin. TNM Classification of malignant tumors. 1987. In INTERNATIONAL UNION AGAINST CANCER (U ICC), edtors, Vol. 4, Springer Verlag, Berlin.Google Scholar
  12. 12.
    Werle B., W. Ebert. W. Klein, and E. Spiess. 1995. Assessment of Cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue Biol Chem. Hoppe-Seyler 376. 157–164.PubMedCrossRefGoogle Scholar
  13. 13.
    Kos J., A. Smid, M. Krasovec, B. Svetic, B. Lenarcic, I. Vrhovec, J Skrk. and Turk V. 1995. Lysosomal proteases cathepsin D, 13, H, L and their inhibitors stefins A and B in head and neck cancer Biol. Chem Hoppe-Seiler 376, 401–405.CrossRefGoogle Scholar
  14. 14.
    Olafsson I., H. Löfberg, M. Abrahamson, and A. Grubb. 1988. Production, characterization and use of monoclonal antibodies against the major extracellular human cysteine proteinase inhibitors cystatin C and kininogen. Scand. J. Lab. Invest. 48, 573–582.CrossRefGoogle Scholar
  15. 15.
    Bradford M. M. 1976. A rapid and sensitive method for the quantitation of microgramm quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254.PubMedCrossRefGoogle Scholar
  16. 16.
    Kaplan E.L., and Meier P. 1958. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53. 457–481.CrossRefGoogle Scholar
  17. 17.
    Abel U., J. Berger, and H. Wiebelt. 1984. Critlevel. An exploratory procedure for the evaluation of quantitative prognostic factors Methods In/: Med. 23, 154–156.Google Scholar
  18. 18.
    Budihna M., P. Strojan, L. Smid, J. Skrk, I. Vrhovec, A. Zupevc, Z. Rudolf, M. Zargi, M. Krasovec, B. Svatic, N. Kopitar-Jerala, and J. Kos. 1996. Prognostic value of cathepsins B. H., L, D and their endogenous inhibitors stefin A and B in head and neck carcinoma. Thal Chem Hoppe-Seyler 377,. 385–390.Google Scholar
  19. 19.
    Sheahan K., S. Shuja, and M. J. Murnane. 1989. Cysteine protease activities and tumor development in human colorectal carcinomas. Cancer Res 49, 3809–3814.PubMedGoogle Scholar
  20. 20.
    Lah T.T., M. Kokalj-Kunovar, B. Strkelj, J. Pungercar, D. Barlic-Maganja, M. Drobnic-Kosorok, L. Kastelic, J. Babnik. R, Golouh, and V. Turk. 1992. Stefins and lysosomal cathepsins B, L and D in human breast carcinoma. bit. J.Cancer 50, 36–44.Google Scholar
  21. 21.
    Mountain C.F. 1991. Surgical treatment of lung cancer. Critic. Rev. Oncol./Hematol. 11, 179–207.CrossRefGoogle Scholar
  22. 1.
    Bond, J. S., and A. J. Barrett, 1993, Proteolysis and protein turnover, Proceeding of the 9th I(.’OP Meeting. Williamsburg, Virginia, U. S. A., Portland Press Proceedings. page X IV.Google Scholar
  23. 2.
    Hoesch, Kurt, 1921, Emil Fischer. sein Leben und sein Werk, Verlag Chemie, G.m.b.11.. Berlin und Leipzig, 480 pages.Google Scholar
  24. 3.
    Abderhalden. Emil. 1906. Lehrbuch der Physiologischen Chemie, Urbahn und Schwarzenberg, Berlin. Wien, 787 pages.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • Eileen Ebert
    • 1
  • Bernd Werle
    • 1
  • Britta Jülke
    • 1
  • Natasa Kopitar-Jerala
    • 2
  • Janko Kos
    • 2
  • Tamara Lah
    • 3
  • Magnus Abrahamson
    • 4
  • Eberhard Spiess
    • 5
  • Werner Ebert
    • 1
    • 6
  1. 1.Thoraxklinik Heidelberg-RohrbachHeidelbergGermany
  2. 2.Department of Biochemistry and Molecular Biology Jamova 39 and Krka, p.o., R&D DivisionJozef Stefan InstituteLjubljanaSlovenia
  3. 3.National Institute of BiologyLjubljanaSlovenia
  4. 4.University Hospital Department of Clinical ChemistryUniversity of LundLundSweden
  5. 5.Biomedizinische Strukturforschung INF 280Deutsches KrebsforschungszentrumHeidelbergGermany
  6. 6.Thoraxklinik Heidelberg-RohrbachHeidelberg-RohrbachGermany

Personalised recommendations